The Technical Analyst
PAVmed Inc [PAVM]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
PAVmed Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.63% $1.950
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.89 mill |
| EPS: | -9.16 |
| P/E: | -0.210 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 9.17 mill |
| Avg Daily Volume: | 0.0644 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.210 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.210 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.599 - 2.30 ( +/- 18.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-22 | Baxter Timothy E | Buy | 65 000 | Common stock |
| 2024-02-22 | White Debra | Buy | 65 000 | Common stock |
| 2024-02-22 | Sparks Ronald M | Buy | 65 000 | Common stock |
| 2024-02-22 | Harvey Joan B | Buy | 65 000 | Common stock |
| 2024-02-22 | Glennon Michael J | Buy | 65 000 | Common stock |
| INSIDER POWER |
|---|
| 99.85 |
| Last 94 transactions |
| Buy: 11 877 994 | Sell: 5 035 719 |
Forecast:
16:00 - $1.940
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.940
Forecast 2: 16:00 - $1.940
Forecast 3: 16:00 - $1.940
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.950 (2.63% ) |
| Volume | 0.0319 mill |
| Avg. Vol. | 0.0644 mill |
| % of Avg. Vol | 49.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PAVM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Latest Press Releases
2024-03-26 19:32:00 - Press Release
Pavmed Provides Business Update And Fourth Quarter And Full Year 2023 Financial Results
Lucid's quarterly revenue increased 33 percent sequentially launched wholly-owned incubator, pmx, to complete development and commercialization of existing portfolio technologies conference call and webcast to be held tomorrow, march 27 th at 8:30 am et new york , march 26, 2024 /prnewswire/ -- pavmed inc. (nasdaq: pavm, pavmz) ("pavmed" or the "company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the company and its subsidiaries, lucid diagnostics inc. (nasdaq: lucd) ("lucid") and veris health inc. ("veris"), and presented financial results for the year ended december 31, 2023...
2024-03-21 09:30:00 - Press Release
Lucid Diagnostics Announces Positive Data From The First Prospective Clinical Validation Study Of Esoguard® Esophageal Precancer Testing In A Screening Population
Prospective va screening study demonstrates excellent esoguard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy authors conclude that esoguard is a "powerful screening tool" for esophageal precancer and cancer new york , march 21, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today announced that investigators at the louis stokes cleveland veterans affairs medical center, led by katarina b. greer, m.d.
2024-03-21 08:30:00 - Press Release
Pavmed Launches Incubator To Advance Existing Pipeline Technologies Including Portio, Esocure And Carpx
The incubator, pmx, and medical device firm hatch medical, execute joint venture agreement to complete their development and commercialization, starting with portio new york, march 21, 2024 /prnewswire/ -- pavmed inc. (nasdaq: pavm) ("pavmed" or the "company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, pmx, to complete development and commercialization of existing portfolio technologies, including the portio™ implantable intraosseous vascular access device ("portio"), esocure™ esophageal ablation device ("esocure"), and carpx® minimally invasive device for carpal tunnel syndrome ("carpx")...
2024-03-20 08:30:00 - Press Release
Lucid Diagnostics Announces Multiple Presentations At The Upcoming Digestive Disease Week (ddw) 2024 Conference
Lucid and collaborators will present data on three studies on esoguard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia new york , march 20, 2024 /prnewswire/ -- lucid diagnostics inc. (nasdaq: lucd) ("lucid" or the "company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of pavmed inc. (nasdaq: pavm, pavmz) ( "pavmed"), today announced that four abstracts related to its groundbreaking technologies, including its esoguard® esophageal dna test, have been accepted for presentation by it and its collaborators at this year's digestive disease week (ddw) annual meeting 2024—the world's premier meeting for digestive disease professionals...
2024-03-13 08:30:00 - Press Release
Pavmed To Hold A Business Update Conference Call And Webcast On March 27, 2024
Conference call and webcast at 8:30 am eastern time new york , march 13, 2024 /prnewswire/ -- pavmed inc. (nasdaq: pavm, pavmz) ("pavmed" or the "company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on wednesday, march 27, 2024, at 8:30 am et. during the call, lishan aklog, m.d.
Latest News
2024-04-10 19:21:31 - Zacks Investment Research
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.
2024-03-27 08:21:17 - Zacks Investment Research
New Strong Buy Stocks for March 27th
RCL, PAVM, BANC, PRLB and IBP have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2023.
2024-03-13 08:30:00 - PRNewsWire
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
2023-12-17 15:00:00 - InvestorPlace
The 3 Most Undervalued Penny Stocks to Buy in December
We cannot end the year without adding a few penny stocks to our portfolio to take advantage of the opportunities coming up in the next cycle. Of course, we must rely on our investment thesis and our own analysis, but here I am to tell you a little about these undervalued penny stocks that are worth analyzing and evaluating to add to our portfolio.
2023-11-15 19:00:12 - Seeking Alpha
PAVmed Inc. (PAVM) Q3 2023 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice President and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ed Woo - Ascendiant Capital Anthony Vendetti - Maxim Group Operator Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.
2023-08-30 11:16:16 - Zacks Investment Research
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-08-16 17:18:07 - Seeking Alpha
PAVmed Inc. (PAVM) Q2 2023 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice President and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ed Woo - Ascendiant Capital Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Operator Good day, and welcome to the PAVmed Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, today's event is being recorded.
2023-05-24 08:00:21 - InvestorPlace
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.
2023-03-17 13:45:27 - Zacks Investment Research
PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know
PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-03-15 12:51:03 - Seeking Alpha
PAVmed Inc. (PAVM) Q4 2022 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Michael Parks – Vice President, Investor Relations Lishan Aklog – Chairman and CEO Dennis McGrath – Chief Financial Officer Conference Call Participants Ross Osborn – Cantor Fitzgerald Frank Takkinen – Lake Street Capital Anthony Vendetti – Maxim Group Ed Woo – Ascendiant Capital Operator Welcome to the PAVmed's Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.